Presence of lipocortins I and IV, but not II and VI, in human platelets  by Eldering, Joyce A. et al.
Volume 318, number 3, 231-234 FEBS 12168 
0 1993 Federation of European Biochemical Societies 00145793/93/S6.00 
March 1993 
Presence of lipocortins I and IV, but not II and VI, in human platelets 
Joyce A. Eldering”, Markus Kocher”, Jeannine M. Clemetsonb, Kenneth J. Clemetsonb, Felix J. Frey” and 
Brigitte M. Frey” 
“Division of Nephrology, Department of Medicine. Inselspital, Berne, Switzerland and bTheodor Kocher Institute, University of Berne, 
Berne. Switzerland 
Received 6 January 1993 
The present investigation revealed the presence of lipocortins I and IV, but not lipocortins II and VI, in human platelets. Lipocortin I was found 
in the Triton-soluble fraction of both resting and thrombin-activated platelets and was not covalently bound to skeletal components. Without 
detergents, when resting platelets were lysed and fractionated in the absence of Ca *+ lipocortin I was found only in the cytosolic fraction, whereas, , 
in the presence of Ca ‘+ lipocortin I was associated only with the crude particulate and not with the membrane nor the cytosohc fractions. , 
Lipocortin; Annexin; Platelet 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Lipocortins (annexins) are widely distributed cal- 
cium-dependent phospholipid- and actin-binding pro- 
teins exhibiting both phospholipase- and coagulation- 
inhibitory activity. They have been suggested to play 
important roles in the regulation of membrane- and 
cytoskeleton-associated vents [ 1,2]. In platelets, upon 
thrombin activation, a series of such events take place 
including Ca2’ mobilization, protein phosphorylation, 
phospholipase activation and exocytosis [3]. Because 
exogenously added LCs have been found to bind to 
activated-platelet phospholipid membranes [4,5], to in- 
hibit platelet phospholipases [6,7] and to be tyrosine- 
phosphorylated [8] all in a Ca”-dependent manner, it 
has been proposed that LCs might play a key role in 
platelet physiology. However, their presence in platelets 
has not been established, except for a recent report 
briefly describing LC V in platelets [9]. 
The present study is the first to identify the presence 
of LCs I and IV, and the absence of detectable amounts 
of LCs II and VI, in human platelets. In addition, the 
subcellular distribution of LC I with respect o Ca2’ was 
further characterized. 
Correspondence address: B.M. Frey, Division of Nephrology, Frei- 
burgstr. 3, CH-3010 Berne, Switzerland. Fax: (41) (31) 25 34 12. 
Abbreviations: LC, lipocortin; rLC, recombinant hpocortin; mAB, 
monoclonal antibody; PMSF, phenylmethylsulfonyl fluoride; NEM, 
N-ethylmaleimide; DTT, dithiothreitol; SDS, sodium dodecyl sulfate; 
PAGE, polyacrylamide gel electrophoresis; IEF, isoelectric focusing; 
Tris, trishydroxymethylaminomethane. 
The purified human rLC I and the antiLC I mAB, 6G6, were 
prepared as previously described [lo]. The placental LC II and the 
mABs specific for LCs I, II, IV and VI were obtained from Zymed 
Laboratory Inc. (CA, USA). Prestained SDS-PAGE protein stand- 
ards were purchased from Bio-Rad Inc. (CA, USA). 
2.1. Platelet isolation 
Human platelets were isolated from citrate-treated blood as previ- 
ously described [l l] with some modifications. Briefly, buffy coats were 
obtained from the Central Laboratory of the Swiss Red Cross Trans- 
fusion Service, approximately 15 h after blood collection, and diluted 
with citrate buffer (30 mM sodium citrate, 100 mM NaCI, 3 mM KCI, 
9.6 mM glucose, 2 mM EDTA, pH 6.5) then centrifuged to yield 
platelet-rich plasma. The platelets were washed twice in 60 mM so- 
dium citrate, 30 mM glucose, 120 mM NaCl, 10 mM EDTA, 0.5 ng/ml 
Iloprost (Schering Inc.), pH 6.5, and once in incubation buffer (10 mM 
Tris, 154 mM NaCI, 5 mM EDTA, pH 6.5). EDTA was replaced by 
EGTA in the case of experiments which examined specifically the 
effects of Ca”. In addition, when Ca*’ was to be included, the platelet 
pellet was resuspended in the incubation buffer without any chelator 
followed by the addition of Ca” (1 mM) and incubated for 30 min at 
37°C in order to replenish intracellular stores of Ca*‘. When a lower 
concentration of Ca” was to be used in subsequent experiments, the 
Ca”-replenished platelets were washed twice in incubation buffer, in 
the absence of any chelator, followed by the addition of Ca” (1OpM). 
Prior to all experiments, aliquots of platelets (3 x 10Yml) were equih- 
brated for at least 30 min at 37°C. 
2.2. Separation of Triton-soluble and -insoluble platelet components 
Aliquots of resting platelets containing EDTA (5 mM) were incu- 
bated without or with bovine thrombin (1 U/ml, Merck Inc.) for 3 min 
at 37°C then immediately solubilized in 1% Triton X-100 containing 
NEM (2 mM) and PMSF (2 mM). The Triton-insoluble components 
were separated into two fractions [12], the cytoskeleton (15,600 x g, 
4 min. 4°C) and the membrane-associated cytoskeleton (150,000 x g, 
15 min, 4’C) and then solubilized in 1% SDS. 
2.3. Lysis and separation of platelet components in the absence of deter- 
gent 
Resting platelets, containing either EGTA (5 mM) or Ca” (10 PM 
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or 1 mM), underwent four rapid freeze/thaw cycles in the presence of 
PMSF (2 mM) and calpain inhibitors I and II (loo&ml; Boehringer 
Mannheim). The resulting lysates were then separated into three frac- 
tions [13]; the crude particulate containing cytoskeleton (13,100 x g, 
20 min. 4”C), membranes (100,000 x g, 1 h, 4°C) and the cytosol. The 
pellets were solubilized by sonication in 1% SDS. 
2.4. Western blot analysis 
Platelet proteins were reduced (100 mM DTT) and denatured 
(lOO’C, 5 min) before being resolved by 12.5% SDS-PAGE or 2- 
dimensional IEF/SDS-PAGE [14]. Platelet proteins were electro- 
phoretically transferred to PVDF Immobilon membrane (Millipore 
Inc.). The LC proteins were detected by treating the blots with the 
respective mABs, followed by treatment with peroxidase-conjugated 
anti-mouse IgG (Bio-Rad Inc.), and then visualized on X-ray film 
(Fuji Inc.) using an enhanced chemilumines~n~ detection system 
(Amersham Inc.). 
3. RESULTS AND DISCUSSION 
In order to determine the presence or absence of LCs 
I, II, IV and VI in human platelets, Western blots of 
platelet proteins were prepared and each individual lane 
was treated with a distinct mAB specific for a single LC. 
Fig. 1 demonstrates the presence of LC I (lane A) at 
3638 kDa and LC IV (lane D) at 33-35 kDa, whereas 
LC II (lanes B, heavy chain, and C, light chain) and LC 
VI (lane E) appear to be absent from human platelets. 
rLC I was recognized only by anti-LC I mAB (Fig. 1) 
and not by the other antiLC mABs (data not shown). 
Glenney [I 51 previously detected two 38 kDa pro- 
teins, LC I and LC II, in human carcinoma cells. These 
proteins share similar structural and functional features 
making their separate analysis difficult. Because the 38 
kDa LC proteins contain conserved omains and might 
exhibit crossreactivity with select ABs, the specificity of 
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Fig. 1. LC proteins identified in human platelets (lanes A-E; 45 pg 
protein/lane) and rLC I (5 ng) detected by Western blot using mABs: 
antiLC I (rLC I and lane A); antiLC II* heavy chain (lane B); antiLC 
II** light chain (lane C); antiLC IV (lane D): antiLC VI (lane E). 
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Fig. 2. LC I is present in the T&on-soluble fraction of resting and 
thrombin-stimulated (1 U/ml) platelets. Western blot using antiLC I 
mAB, 6G6. Each lane contains the equivalent of 5 x 10’ platelets: 
whole platelets olubilized in SDS (lanes A); Triton-insoluble cytoskel- 
eton (lanes B); Triton-insoluble membrane skeleton (lanes C); Triton- 
soluble components (lanes D). rLC I (5 ng). 
the antiLC I mAB, 6G6, used in the subsequent experi- 
ments, had to be established. Therefore, rLC I and pla- 
cental LC II protein preparations were subjected to 
Western blot analysis. The mAB, 6G6, recognized a 38 
kDa protein corresponding to LC I but not LC II, 
whereas an antiLC II mAB detected only LC II but not 
LC I (data not shown). A 68 kDa band was recognized 
by 6G6 in the placental preparation of LC II and may 
represent a crosslinked dimeric form of LC I known to 
exist in placenta [16,17]. Furthermore, when platelet 
proteins were subjected to 2-dimensional IEFISDS- 
PAGE followed by Western blot anaiysis, only a single 
protein was recognized by the mAB, 6G6, at the appro- 
priate pI(6.5) for LC I (data not shown), confirming the 
presence of LC I but not LC II in human platelets. 
LC I is known to associate with both actin filaments 
in vitro [ 151 and in intact human carcinoma cells, with 
the inner plasma membrane [16]. To examine the subcel- 
lular distribution of LC I in platelets, resting and throm- 
bin-stimulated platelets were solubilized in 1% Triton 
X-100 then separated into three fractions. The results in 
Fig. 2 show that all of LC I, in whole unfractionated 
platelets (lane A), is entirely in the Triton-soluble frac- 
tion (lane D) and is not covalently bound to the cy- 
toskeletal (lane B) nor membrane-associated cytoskel- 
eta1 (lane C) components. LC I remained in the Triton- 
soluble fraction and did not shift to the cytoskeletal 
fractions even after thrombin-stimulation (Fig. 2) indi- 
cating that LC I is not covalently bound to skeletal 
components upon platelet activation. 
Since Ca2+ is a second messenger for platelet activa- 
tion [18] and can also influence the binding affinity of 
LC I for many cellular components 115,161, the impact 
of Ca” on the subcellular distribution of LC I in plate- 
lets was investigated in the absence of detergents. Fig. 
3 shows the distribution of LC I in whole platelets (lanes 
A) which have been lysed and separated into three 
subcellular fractions (crude particulate, lanes B; crude 
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Fig. 3. Platelet subcellular localization of LC I changes with the ab- 
sence (EGTA 5 mM) or presence of Ca*’ (10 ,uM or 1 mM). Western 
blot using antiLC I mAB, 6G6. Each lane contains the equivalent of 
3 x 10’ whole (lanes A) or fractionated platelets: crude particulate 
(lanes B); crude membrane (lanes C); cytosol (lanes D). rLC I (5 ng). 
membrane, lanes C; and cytosol, lanes D) in the absence 
(EGTA 5 mM) or presence of 10 PM or 1 mM Ca*+. The 
results in Fig. 3 demonstrate that Ca2’, even within the 
physiological ,uM range sufficient to stimulate secretory 
exocytosis [181, causes a shift in the subcellular distribu- 
tion of LC I from the cytosol (lanes D) to the crude 
particulate (lanes B) in human platelets. The crude par- 
ticulate contains cytoskeletal filaments and granules to 
which LCs have been reported to associate with in a 
Ca2’-dependent manner in sheep anterior pituitary cells 
[19], human neutrophils [20] and cell-free systems [15]. 
The results of the present study suggest that LC I, po- 
tentially regulated by Ca2’, may have a functional role 
during platelet activation. 
Interestingly, when platelets were lysed in the pres- 
ence of Ca2+ (1 mM), LC I was completely degraded and 
this degradation was blocked specifically by calpain in- 
hibitors I and II, and not by NEM nor PMSF (data not 
shown). Calpain is a Ca2’-dependent protease, abun- 
dant in platelets, without an established function [21]. 
It is also worthy of mention that LC I was inconsistently 
found in the crude particulate fraction, in addition to 
the cytosolic fraction, in the absence of Ca*’ (EDTA 5 
mM), only when platelets were lysed by sonication (data 
not shown) rather than the freeze/thaw method used in 
the present study. 
Table I presents a summary of the LC proteins with 
their possible biological functions and their presence in 
platelets. Previously, a 40 kDa protein in platelets has 
been claimed to be immunologically similar to LC [22] 
and there are proteins in this mass range that are tyro- 
sine-phosphorylated upon platelet activation [23,24]. 
Because both LCs I and II fulfill these criteria [8] either 
protein may be the proposed LC in platelets. The results 
in the present study indicate that this aforementioned 
40 kDa protein in platelets is LC I and not LC II. 
Further investigations are necessary to establish the bi- 
ological relevance of LCs during platelet activation. 
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Table I 
Characteristics and functions of lipocortins 
Possible biological activities 
Lipocortin 
I 
11: 
III 
IV 
V 
VI 
M.W. Isoelectric Presence Phosph- Inhibition Inhibition Anti- Others 
point in platelets orylated of PLA, of PLC coagulant 
38 kDa 6.5 p1 Yes Yes Yes Yes Yes Endogenous 
t32,lOl (see results, 8) (Fig. 1) [WI [6,321 171 1301 substrate for 
tyrosine kinase 
134381 
38 kDa 7.9 p1 Yes Yes Yes Yes Substrate for 
t331 (341 (F&) [341 ]251 ]71 ]301 tyrosine kinase 
[341 
35 kDa 5.9 p1 N.D. N.D. Yes N.D. Yes _ 
[29,30] 1301 v91 1301 
35 kDa 6.0 p1 Yes N.D. Yes N.D. Yes _ 
P81 P81 (Fig. 1) V81 P81 
35 kDa 4.8 p1 Yes N.D. Yes N.D. Yes _ 
[26,28,29] P81 P41 128,291 P6281 
68 kDa 6.1 p1 No Yes Yes N.D. Yes Modifier of 
PWl [301 (Fig. 1) v71 ~291 [301 Ca*’ channels [31] 
* Heavy chain only; N.D., not determined. 
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